Compounded Semaglutide Shortage Ends as FDA Removes Drug from Shortage List
GLP-1 Authority Editorial Team
Medical News Desk
The FDA officially removed semaglutide from its drug shortage list, signaling that compounding pharmacies must phase out compounded versions by mid-2026 as branded supply normalizes.
Key Points
- FDA removed semaglutide from the drug shortage list effective March 2026
- Compounding pharmacies have until June 2026 to phase out compounded semaglutide
- Patients on compounded semaglutide should transition to branded versions
- Tirzepatide remains on the shortage list — compounded versions still permitted
- FDA has issued warning letters to pharmacies selling unapproved semaglutide products
End of the Semaglutide Shortage
The U.S. Food and Drug Administration has officially removed semaglutide from its drug shortage list, citing normalized supply of branded products from the manufacturer. The shortage, which began in 2022 as demand for GLP-1 medications surged, had allowed compounding pharmacies to legally produce copies of semaglutide under FDA's shortage exemption. With the shortage resolved, this exemption no longer applies.
What This Means for Compounding Pharmacies
Under FDA regulations, compounding pharmacies may only produce copies of FDA-approved drugs when those drugs are on the official shortage list. With semaglutide removed from the list, compounding pharmacies — including 503A traditional pharmacies and 503B outsourcing facilities — are required to cease production of compounded semaglutide. The FDA has set a compliance deadline of June 30, 2026, giving pharmacies time to wind down production and transition patients.
Impact on Patients
An estimated 500,000 to 1,000,000 patients in the United States are currently receiving compounded semaglutide, primarily through telehealth platforms that offered lower-cost alternatives to branded GLP-1 medications. These patients will need to transition to branded semaglutide products or alternative GLP-1 medications. The cost difference is significant: compounded semaglutide has been available for $150 to $400 per month, compared to $900 to $1,350 per month for branded versions without insurance.
Tirzepatide: Still on the Shortage List
Importantly, tirzepatide remains on the FDA drug shortage list as of April 2026, meaning compounded tirzepatide is still legally permitted. Several telehealth platforms have already begun transitioning patients from compounded semaglutide to compounded tirzepatide. However, patients and providers should monitor the FDA shortage list closely, as tirzepatide's status could change as the manufacturer continues to expand manufacturing capacity.
FDA Enforcement Actions
The FDA has issued warning letters to several compounding pharmacies and telehealth platforms that have continued to sell compounded semaglutide after the shortage resolution, or that have been selling products labeled as "semaglutide" that do not contain the active pharmaceutical ingredient. Patients should be cautious about purchasing GLP-1 medications from unverified sources and should only obtain medications through licensed pharmacies with a valid prescription.
What Patients Should Do
If you are currently taking compounded semaglutide, contact your prescribing provider as soon as possible to discuss your options. Your provider may transition you to a branded GLP-1 medication, switch you to a different GLP-1 agent, or help you explore insurance coverage options. Do not abruptly stop your medication without medical guidance, as this can lead to weight regain. Our Cost and Insurance guide provides detailed information on manufacturer savings programs and insurance coverage options.
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.